Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
4-{5-[(Z)-(2-imino-4-oxo-1,3-thiazolidin-5-yldiene)methyl]furan‑2‑yl}benzenesulfonamide is a synthetic small molecule with the molecular formula C14H11N3O4S2 and a molecular weight of approximately 349.39 g/mol[5][10]. It contains a thiazolidinone core linked via a furan ring to a benzenesulfonamide group. The compound is classified as an experimental chemical entity and has not been approved for clinical use in any country[6]. There are no known brand names or marketed formulations. Its mechanism of action, pharmacological activity, and therapeutic indications have not been established in the literature or regulatory databases[6][7]. It is primarily referenced in chemical biology resources as an experimental or screening compound.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 4-{5-[(Z)-(2-imino-4-oxo-1,3-thiazolidin-5-ylidene)methyl]furan-2-yl}benzenesulfonamide.